{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:47Z","timestamp":1790286947382,"version":"4.1.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:p>Cutaneous eruptions are among the most common immune-related adverse events (irAEs) associated with anti-programmed cell death protein 1\/programmed cell death ligand 1 therapy, and are often clinically and histologically characterized as lichenoid. Nonlichenoid patterns may also occur and are likely to be encountered by surgical pathologists, given the increasing clinical use of these agents. The purpose of this study is to describe the histopathologic features of nonlichenoid cutaneous irAEs from patients receiving anti-programmed cell death protein 1\/programmed cell death ligand 1 therapies for a variety of underlying advanced malignancies. Sixteen patients with 17 biopsied eruptions were included from 2 academic institutions with extensive experience administering and monitoring responses to immune checkpoint blockade as well as treating the potential side effects. Eruptions occurred a median of 10 days (range, 1 d to 11.4 mo) after treatment initiation. Nearly half of specimens demonstrated either a psoriasiform\/spongiotic or an urticarial-type reaction pattern on histologic review. Patterns consistent with Grover disease, bullous pemphigoid, and granulomatous dermatitis were also observed. Nearly two-thirds of patients required systemic corticosteroids for treatment of the cutaneous irAE, and 19% of patients discontinued immunotherapy due to their skin eruptions. 75% of patients showed an objective antitumor response. The diverse array of nonlichenoid cutaneous irAE presented here should reflect and inform the scope of histologic patterns encountered by the practicing surgical pathologist. Such eruptions are seen in patients with a variety of underlying tumor types, many of whom ultimately demonstrate a favorable response to immune checkpoint blockade.<\/jats:p>","DOI":"10.1097\/pas.0000000000000900","type":"journal-article","created":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T15:37:02Z","timestamp":1502897822000},"page":"1381-1389","source":"Crossref","is-referenced-by-count":66,"title":["Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade"],"prefix":"10.1097","volume":"41","author":[{"given":"Genevieve J.","family":"Kaunitz","sequence":"first","affiliation":[{"name":"Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Loss","sequence":"additional","affiliation":[{"name":"Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Rizvi","sequence":"additional","affiliation":[{"name":"Medicine, Thoracic Oncology Service"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Ravi","sequence":"additional","affiliation":[{"name":"Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Cuda","sequence":"additional","affiliation":[{"name":"Dermatology"},{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen B.","family":"Bleich","sequence":"additional","affiliation":[{"name":"Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Esandrio","sequence":"additional","affiliation":[{"name":"Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbal","family":"Sander","sequence":"additional","affiliation":[{"name":"Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung T.","family":"Le","sequence":"additional","affiliation":[{"name":"Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Diaz","sequence":"additional","affiliation":[{"name":"Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[{"name":"Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Drake","sequence":"additional","affiliation":[{"name":"Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center"},{"name":"The Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis J.","family":"Hollmann","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[{"name":"Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Hellmann","sequence":"additional","affiliation":[{"name":"Medicine, Thoracic Oncology Service"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J.","family":"Lipson","sequence":"additional","affiliation":[{"name":"Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis M.","family":"Taube","sequence":"additional","affiliation":[{"name":"Dermatology"},{"name":"Pathology"},{"name":"Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma","volume":"151","author":"Ohtsuka","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R8-20230922","first-page":"e89","article-title":"Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma","volume":"30","author":"Kato","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/rheumatology\/kew281","article-title":"Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer","volume":"55","author":"Law-Ping-Man","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2340\/00015555-2212","article-title":"Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma","volume":"96","author":"Matsumura","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/1346-8138.13450","article-title":"Case of de novo psoriasis possibly triggered by nivolumab","volume":"44","author":"Murata","year":"2016","journal-title":"J Dermatol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jdcr.2016.05.009","article-title":"Development of bullous pemphigoid during nivolumab therapy","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma","volume":"149","author":"Danlos","year":"2016","journal-title":"Chest"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","article-title":"Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature","volume":"4","author":"Reuss","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","article-title":"Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy","volume":"2","author":"Suozzi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/CJI.0000000000000112","article-title":"Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma","volume":"39","author":"Nayar","year":"2016","journal-title":"J Immunother"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","article-title":"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy","volume":"43","author":"Schaberg","year":"2016","journal-title":"J Cutan Pathol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/DAD.0000000000000587","article-title":"Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on antiprogramed cell death-1 (anti-PD-1) therapy with or without ipilimumab","volume":"39","author":"Chou","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.5858\/133.9.1490","article-title":"Grover disease (transient acantholytic dermatosis)","volume":"133","author":"Weaver","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","article-title":"Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma","volume":"152","author":"Totonchy","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CJI.0000000000000121","article-title":"Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC)","volume":"39","author":"Chia","year":"2016","journal-title":"J Immunother"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jdcr.2016.06.012","article-title":"Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanoma","volume":"2","author":"Mutgi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"e1231292","DOI":"10.1080\/2162402X.2016.1231292","article-title":"Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer","volume":"5","author":"Hasan Ali","year":"2016","journal-title":"Oncoimmunology"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.autrev.2015.01.006","article-title":"Atypical presentations of bullous pemphigoid: clinical and immunopathological aspects","volume":"14","author":"Cozzani","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1158\/0008-5472.CAN-16-0194","article-title":"Assessing immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201710000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T18:26:47Z","timestamp":1695407207000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201710000-00008"}},"subtitle":["Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern"],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000900","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.728769523.793545831","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.728769523.793538390","asserted-by":"object"}]},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}